Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Uterine Hemorrhage

ClinicalTrials.gov lists 843 trials for Uterine Hemorrhage or a narrower condition beneath it. Bayer has the most among industry and government lead sponsors, with 21.

MeSH D014592 Urogenital Diseases C12 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 26 Phase 1/2 Phase 1/2 13 Phase 2 Phase 2 39 Phase 2/3 Phase 2/3 8 Phase 3 Phase 3 103 Phase 4 Phase 4 98 Not applicable Not applicable 365 Observational Observational 190 Phase 1 Phase 1 26 Phase 1/2 Phase 1/2 13 Phase 2 Phase 2 39 Phase 2/3 Phase 2/3 8 Phase 3 Phase 3 103 Phase 4 Phase 4 98 Not applicable Not applicable 365 Observational Observational 190

Trials per phase (log scale)

1 more section with rows

80 of the 843 trials are tagged with Uterine Hemorrhage itself; the rest are tagged with a narrower condition beneath it.

Get the Uterine Hemorrhage report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Uterine Hemorrhage trials start? (30)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 63

1994: 1 trials (Phase 3 1) 1997: 1 trials (Phase 3 1) 1999: 1 trials (Phase 2 1) 2000: 1 trials (Not applicable 1) 2001: 2 trials (Not applicable 1, Phase 2 1) 2002: 7 trials (Observational 1, Not applicable 2, Phase 3 3, Phase 2 1) 2003: 7 trials (Observational 1, Not applicable 2, Phase 3 3, Phase 2 1) 2004: 7 trials (Not applicable 1, Phase 4 2, Phase 3 3, Phase 2 1) 2005: 14 trials (Observational 1, Not applicable 9, Phase 3 4) 2006: 13 trials (Not applicable 4, Phase 4 3, Phase 3 5, Phase 2 1) 2007: 14 trials (Not applicable 6, Phase 4 2, Phase 3 4, Phase 2 1, Phase 1/2 1) 2008: 18 trials (Observational 4, Not applicable 8, Phase 4 3, Phase 3 1, Phase 2 2) 2009: 12 trials (Observational 4, Not applicable 3, Phase 4 3, Phase 3 1, Phase 2 1) 2010: 18 trials (Observational 5, Not applicable 7, Phase 4 6) 2011: 33 trials (Observational 3, Not applicable 18, Phase 4 4, Phase 3 3, Phase 2/3 1, Phase 2 1, Phase 1/2 1, Phase 1 2) 2012: 39 trials (Observational 7, Not applicable 20, Phase 4 3, Phase 3 5, Phase 2/3 1, Phase 2 1, Phase 1/2 2) 2013: 48 trials (Observational 9, Not applicable 20, Phase 4 5, Phase 3 7, Phase 2/3 1, Phase 2 3, Phase 1 3) 2014: 44 trials (Observational 7, Not applicable 22, Phase 4 7, Phase 3 5, Phase 2 2, Phase 1/2 1) 2015: 39 trials (Observational 6, Not applicable 12, Phase 4 3, Phase 3 9, Phase 2/3 1, Phase 2 2, Phase 1/2 3, Phase 1 3) 2016: 46 trials (Observational 10, Not applicable 14, Phase 4 10, Phase 3 4, Phase 2/3 2, Phase 2 4, Phase 1/2 1, Phase 1 1) 2017: 31 trials (Observational 6, Not applicable 11, Phase 4 4, Phase 3 10) 2018: 55 trials (Observational 9, Not applicable 19, Phase 4 12, Phase 3 9, Phase 2 3, Phase 1 3) 2019: 48 trials (Observational 17, Not applicable 20, Phase 4 4, Phase 3 4, Phase 2/3 1, Phase 1 2) 2020: 56 trials (Observational 17, Not applicable 23, Phase 4 5, Phase 3 5, Phase 2 2, Phase 1/2 1, Phase 1 3) 2021: 37 trials (Observational 15, Not applicable 16, Phase 4 2, Phase 3 2, Phase 2 1, Phase 1/2 1) 2022: 41 trials (Observational 8, Not applicable 21, Phase 4 5, Phase 3 3, Phase 2/3 1, Phase 2 2, Phase 1 1) 2023: 41 trials (Observational 8, Not applicable 24, Phase 4 4, Phase 3 1, Phase 1/2 2, Phase 1 2) 2024: 48 trials (Observational 20, Not applicable 18, Phase 4 3, Phase 3 4, Phase 2 2, Phase 1 1) 2025: 63 trials (Observational 16, Not applicable 36, Phase 4 4, Phase 3 2, Phase 2 2, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 52
2025 63
2024 48
2023 41
2022 41
2021 37
2020 56
2019 48
2018 55
2017 31

Showing 10 of 30 earlier years.

Start your 14-day trial Email me all 30 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 66 trials starting in 2026 and about 62 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 33 months from start to primary completion across 63 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 547 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Uterine Hemorrhage trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 26
Phase 1/2 13
Phase 2 39
Phase 2/3 8
Phase 3 103
Phase 4 98
Not applicable 365
Observational 190
Expanded access 1

How many Uterine Hemorrhage trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 47
Recruiting 76
Enrolling by invitation 2
Active, not recruiting 13
Completed 502

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Uterine Hemorrhage trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Bayer 21
AbbVie 8
Abbott 7
Ferring Pharmaceuticals 6

Which drugs are being tested for Uterine Hemorrhage? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
MisoprostoL 66
Elagolix 7
Levonorgestrel 7
Asoprisnil 7
Ergonovine 7

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
IM Oxytocin 94
acid tranexamic 67
carbetocin 100 µg 52
Estradiol /norethindrone acetate (E2/NETA) 9
Ulipristal Acetate - open label 8

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Uterine Hemorrhage trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Admission to ICU 39 1
ANAEMIA 16 5
Menorrhagia 11 6
UTERINE LEIOMYOMA 10 4
Anaemia 8 7

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Uterine Hemorrhage? (309)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Differences in pain, bleeding, and satisfaction during medical abortion at very early gestations. Acta obstetricia et gynecologica Scandinavica 2025 Yes
Endometrial Biopsy Versus No Endometrial Biopsy with a Normal-Appearing Cavity During In-office Hysteroscopy for Postmenopausal Bleeding: A Randomized Controlled Trial. Journal of minimally invasive gynecology 2025 Yes
Perimenopausal abnormal uterine bleeding. Maturitas 2024 Yes
Operative Complications, Vaginal Bleeding, and Practice Considerations for Patients on Testosterone Undergoing Gender-Affirming Hysterectomy. Journal of minimally invasive gynecology 2024 Yes
The effectiveness of desogestrel for endometrial protection in women with abnormal uterine bleeding-ovulatory dysfunction: a non-inferiority randomized controlled trial. Scientific reports 2022 Yes

Showing 5 of 309 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages